Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma
(NASDAQ: PHIO) Delayed: 1.01 -0.02 (1.94%)
Previous Close $1.03    52 Week High $ 
Open $1.04    52 Week Low $ 
Day High $1.05    P/E N/A 
Day Low $1.00    EPS $ 
Volume 78,708